Latest Insider Transactions at Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a real-time view of insider transactions for Kal Vista Pharmaceuticals, Inc. (KALV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KalVista Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KalVista Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
25,800
-26.76%
|
$696,600
$27.01 P/Share
|
|
Jun 01
2021
|
Michael David Smith Senior VP, Development |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$195,000
$26.83 P/Share
|
|
Jun 01
2021
|
Michael David Smith Senior VP, Development |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$60,000
$8.39 P/Share
|
|
May 03
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-9.96%
|
$144,000
$24.84 P/Share
|
|
May 03
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+9.06%
|
$60,000
$10.21 P/Share
|
|
May 03
2021
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-10.42%
|
$120,000
$24.84 P/Share
|
|
Apr 29
2021
|
Thomas Andrew Crockett CEO |
SELL
Bona fide gift
|
Direct |
4,750
-2.98%
|
-
|
|
Apr 29
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
40,886
-100.0%
|
$1,022,150
$25.04 P/Share
|
|
Apr 29
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
40,886
+36.47%
|
$408,860
$10.73 P/Share
|
|
Apr 28
2021
|
Michael David Smith Senior VP, Development |
SELL
Open market or private sale
|
Direct |
10,014
-100.0%
|
$250,350
$25.76 P/Share
|
|
Apr 28
2021
|
Michael David Smith Senior VP, Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,014
+50.0%
|
$80,112
$8.39 P/Share
|
|
Apr 28
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
36,127
-70.84%
|
$903,175
$25.49 P/Share
|
|
Apr 28
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
36,127
+50.0%
|
$252,889
$7.91 P/Share
|
|
Apr 27
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
11,017
-100.0%
|
$275,425
$25.79 P/Share
|
|
Apr 27
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
11,017
+50.0%
|
$77,119
$7.91 P/Share
|
|
Apr 01
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.98%
|
$270,000
$27.27 P/Share
|
|
Feb 23
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.41%
|
$330,000
$33.49 P/Share
|
|
Feb 23
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
31,000
-9.98%
|
$1,023,000
$33.4 P/Share
|
|
Feb 23
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
29,642
-8.49%
|
$978,186
$33.49 P/Share
|
|
Feb 23
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,642
+23.85%
|
$177,852
$6.74 P/Share
|
|
Feb 23
2021
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-6.35%
|
$495,000
$33.49 P/Share
|
|
Feb 07
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+12.79%
|
-
|
|
Feb 07
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+33.33%
|
-
|
|
Jan 04
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.57%
|
$180,000
$18.49 P/Share
|
|
Dec 30
2020
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
358
-1.09%
|
$7,160
$20.04 P/Share
|
|
Dec 30
2020
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
358
+1.08%
|
$2,148
$6.74 P/Share
|
|
Nov 02
2020
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-7.62%
|
$102,000
$17.14 P/Share
|
|
Oct 30
2020
|
Albert Cha Director |
BUY
Open market or private purchase
|
Indirect |
115,686
+4.94%
|
$1,966,662
$17.26 P/Share
|
|
Oct 29
2020
|
Thomas Andrew Crockett CEO |
SELL
Bona fide gift
|
Direct |
6,000
-3.24%
|
-
|
|
Oct 29
2020
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-7.36%
|
$85,000
$17.48 P/Share
|
|
Oct 21
2020
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
22,545
-3.56%
|
$405,810
$18.33 P/Share
|
|
Oct 21
2020
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
9,007
-5.26%
|
$162,126
$18.2 P/Share
|
|
Oct 21
2020
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
6,044
-4.17%
|
$108,792
$18.35 P/Share
|
|
Oct 20
2020
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
15,994
-3.47%
|
$271,898
$17.64 P/Share
|
|
Oct 20
2020
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
7,900
-4.2%
|
$134,300
$17.63 P/Share
|
|
Oct 20
2020
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,942
-4.95%
|
$135,014
$17.64 P/Share
|
|
Oct 16
2020
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
993
-1.03%
|
$16,881
$17.0 P/Share
|
|
Oct 16
2020
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.1%
|
$15,538
$17.0 P/Share
|
|
Oct 16
2020
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,261
-0.53%
|
$21,437
$17.01 P/Share
|
|
Apr 29
2020
|
Thomas Andrew Crockett CEO |
SELL
Bona fide gift
|
Direct |
3,000
-1.27%
|
-
|
|
Oct 12
2017
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
850,000
+37.1%
|
$6,800,000
$8.5 P/Share
|
|
Oct 12
2017
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,726,481
-50.01%
|
$15,538,329
$9.26 P/Share
|
|
Oct 11
2017
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,519
-2.02%
|
$355,190
$10.21 P/Share
|
|
Oct 10
2017
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
963,283
-6.91%
|
$11,559,396
$12.78 P/Share
|